CorMedix Inc
CRMD Healthcare Biotechnology
CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.
Follow CRMD
CorMedix Inc (CRMD) EV/Sales
As of 16 October 2026, CorMedix Inc (CRMD) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from −6.8× (March 2018) to 4,730× (April 2024); the current reading is higher than 1% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.7× | (72.67%) |
| FY2024 | 9.8× | (99.42%) |
| FY2022 | 1,683× | 201.67% |
| FY2021 | 558× | (19.87%) |
| FY2020 | 696× | 33.94% |
| FY2019 | 520× | 116.44% |
| FY2018 | 240× | 363.58% |
| FY2017 | 51.8× | (73.95%) |
| FY2016 | 199× | 48.91% |
| FY2015 | 134× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.1× | (13.87%) |
| Mar 2026 | 1.3× | (52.66%) |
| Dec 2025 | 2.7× | (41.05%) |
| Sep 2025 | 4.5× | (14.76%) |
| 37 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| CRMD CorMedix Inc | 1.0× |
| PHAT Phathom Pharmaceuticals, Inc. compare | 2.4× |
| ZVRA Zevra Therapeutics, Inc. compare | 3.4× |
| VALN Valneva SE Sponsored ADR compare | 3.5× |
| STTK Shattuck Labs, Inc. compare | 88.3× |
| DBVT DBV Technologies S.A. compare | 124× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 403× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)